Clinical Trials Logo

Chronic Renal Failure clinical trials

View clinical trials related to Chronic Renal Failure.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT01229072 Suspended - Clinical trials for Chronic Renal Failure

Safe Use of Heparin Sodium in Patients With Chronic Renal Failure.

Heparin
Start date: July 2008
Phase: Phase 2/Phase 3
Study type: Interventional

The Heparin form a complex with a plasma protein, antithrombin III (ATIII), which is an endogenous anticoagulant. This complex inhibits the formation of thrombin and accelerates its destruction. Moreover, heparin and other proteases ATIII inactivate the clotting cascade, especially the anti-activated factor X. The end result of these actions is the inhibition of biochemical training and synthesis of certain clotting factors that activators of critical functions in the genesis of a blood clot. Patients with chronic renal failure (CRF) who use the treatment of hemodialysis need a system of anticoagulation with the direct thrombin inhibitor and / or heparinóides to prevent thrombosis. Based on clinical studies, to control the level of plasma heparin in patients with CRF is essential. Evidence of clotting as APTT, TP, ACT and proof of the activity of anti-factor Xa should be used as a substrate of protection for those patients on hemodialysis.